Journal
MEDICAL HYPOTHESES
Volume 154, Issue -, Pages -Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.mehy.2021.110661
Keywords
COVID-19; Cytokine storm; Multi-organ failure; Intestinal dysbiosis; Short-chain fatty acids; Butyrate
Categories
Ask authors/readers for more resources
The world is currently facing the COVID-19 pandemic with severe impact on many countries, necessitating urgent discovery of biomarkers and effective treatments to prevent disease progression. Recent investigations suggest a possible link between intestinal dysbiosis and the pathophysiology of COVID-19.
The world is currently facing the COVID-19 pandemic that is taking a heavy toll on several countries. While many infected patients have a good prognosis, in some cases the progression can be serious and even lead to death. The commonly seen complications are a cytokine storm and multi-organ failure that require intensive care. The mortality of critically ill patients depends on age, sex, immune state or co-morbidities. There is an urgent need to discover a biomarker to identify early on patients at risk of developing serious complications and to find an effective treatment that could prevent disease progression and critical states. Recent investigations have pointed to the possible contribution of intestinal dysbiosis to the pathophysiology of COVID-19. Herein, we hypothesize that butyrate, a short-chain fatty acid initially produced by the gut microbiota, could be administered as supportive therapy to prevent immune system activation and disease progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available